Navigation Links
Adamas Pharmaceuticals Signs CRADA With U.S. Navy to Conduct Preclinical Studies of Triple-Combination Antiviral Drug Therapy for Influenza A, Including the Novel H1N1 Pandemic Strain
Date:8/18/2009

Emeryville, Calif., Aug. 18 /PRNewswire/ -- Adamas Pharmaceuticals, Inc., a privately held company, announced today that it has entered into a Cooperative Research and Development Agreement (CRADA) with the United States Naval Health Research Center for preclinical studies evaluating Adamas' triple combination antiviral drug (TCAD) therapy for influenza A, including novel influenza A/H1N1. TCAD therapy includes Adamas' investigational proprietary fixed-dose oral combination drug, to be administered adjunctively with a neuraminidase inhibitor, including Tamiflu (oseltamivir phosphate, Roche).

Under the CRADA, the U.S. Naval Health Research Center will conduct comparative tests of Adamas' TCAD therapy against various strains of the influenza A virus, including seasonal influenza (H1N1, H3N2), avian influenza (H5N1) and novel influenza A/H1N1. The purpose of these studies is to assess the in vitro activity of TCAD therapy against various circulating and/or highly pathogenic strains of the influenza A virus, as well as to compare the in vitro activity of TCAD therapy to other pharmaceutical agents when used alone or in double combination. Data from these experiments will be used to advance the development of Adamas' TCAD therapy as a potential broad-spectrum antiviral therapy for serious infections caused by influenza A viruses. In addition, Adamas and the Navy's work with the novel influenza A/H1N1 virus may provide insight into this widespread public health issue.

"Collaborating with the U.S. Naval Health Research Center, with its leadership in medicine and its seminal work in discovering the novel influenza A/H1N1 virus, will significantly advance Adamas' efforts to develop TCAD therapy in response to the influenza pandemic," said Gregory Went, Ph.D., Chief Executive Officer and Chairman of Adamas. "We look forward to partnering with the Naval Health Research Center to generate d
'/>"/>

SOURCE Adamas Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Eiger BioPharmaceuticals Announces Initiation of CLEAN-1 HCV Phase 1b Trial
2. Access Pharmaceuticals Provides Update on ProLindac Clinical Development Program
3. Poniard Pharmaceuticals Announces Positive Cardiac Safety Data From Picoplatin Phase 1 Trial Supporting NDA Filing
4. Idenix Pharmaceuticals Successfully Completes Proof-of-Concept Study of IDX184 for the Treatment of Hepatitis C Virus (HCV)
5. Cardax Pharmaceuticals Nominates Clinical Candidate Heptax for Liver Disease; Heptax Ameliorates Inflammation and Oxidative Stress Related to Liver Disease and Metabolic Syndrome
6. BioCryst Pharmaceuticals Reports Positive Results of Shionogi & Co. Sponsored Phase 3 Studies of i.v. Peramivir for Influenza
7. Tibotec Pharmaceuticals Announces Agreement to Develop and Commercialize a New Fixed-Dose Combination of TMC278 and Truvada(R) With Gilead Sciences
8. Keryx Biopharmaceuticals, Inc. Commences Phase 1 Study of KRX-0401 (Perifosine) in Recurrent Pediatric Solid Tumors at Memorial Sloan-Kettering Cancer Center
9. Bioniche Life Sciences Inc. and Endo Pharmaceuticals Sign Licensing Agreement for Urocidin(TM)
10. Procter & Gamble Pharmaceuticals Launches Asacol(R) HD (mesalamine) Delayed-Release Tablets
11. King Pharmaceuticals Showcases Data From Pain Pipeline of Medicines Designed to Deter Common Methods of Non-Therapeutic Use
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/14/2014)... Ore. , Jan. 14, 2014 /PRNewswire-iReach/ -- Acumed,s ... a targeting guide with accompanying instrumentation to place and ... adjunct to the soft tissue (e.g. ligament) repair or ... tissue repair heals. (Photo: http://photos.prnewswire.com/prnh/20140114/MN45636 ) ...
(Date:1/14/2014)... 2014 NineSigma , Inc., the leading innovation ... Leadership Summit , May 14-16, 2014 at the Global ... . This is the premier ... breakthrough achievements through open innovation. Participants will learn how ...
(Date:1/14/2014)... 14, 2014   Evidera , a leading provider of ... Center for Drug Evaluation and Research (CDER), U.S. Food ... guidance document for a patient-reported outcome (PRO) measure in ... Disease Tool [EXACT] for Measurement of Symptoms of Acute ...
Breaking Medicine Technology:Acumed introduces the Scapho-Lunate Inter Carpal (SLIC) Screw System 2Acumed introduces the Scapho-Lunate Inter Carpal (SLIC) Screw System 3Expect the Unexpected from Leading Global Innovators at NineSigma Leadership Summit, Sharing Winning Strategies to Advance Innovation 2Expect the Unexpected from Leading Global Innovators at NineSigma Leadership Summit, Sharing Winning Strategies to Advance Innovation 3Expect the Unexpected from Leading Global Innovators at NineSigma Leadership Summit, Sharing Winning Strategies to Advance Innovation 4Evidera Announces Release of FDA Draft Guidance on Use of the "EXACT" to Measure Symptoms of COPD Exacerbations 2Evidera Announces Release of FDA Draft Guidance on Use of the "EXACT" to Measure Symptoms of COPD Exacerbations 3Evidera Announces Release of FDA Draft Guidance on Use of the "EXACT" to Measure Symptoms of COPD Exacerbations 4
... Medarex, Inc. (Nasdaq:, MEDX ) announced today ... non-fucosylated version of MDX-060 that targets CD30, a,marker ... malignant cells of,Hodgkin,s lymphoma (HL) as well as ... potency and efficacy in cell lines when,compared to ...
... TEL AVIV, Israel, December 8 InspireMD, Ltd. announced,that ... use in Israel,by the Israeli Ministry of Health. , ... system presents a novel combination of a coronary,stent merged ... by an expandable, flexible fishnet style, micron level knit,sleeve ...
Cached Medicine Technology:Medarex Announces Enhanced Activity Data with Second Generation Anti-CD30 Antibody for Malignant Lymphoma 2Medarex Announces Enhanced Activity Data with Second Generation Anti-CD30 Antibody for Malignant Lymphoma 3MGuard(TM) Coronary Stent System Approved in Israel 2MGuard(TM) Coronary Stent System Approved in Israel 3
(Date:4/17/2014)... most popular vaccine brands for children may not be ... some cost factors when choosing vaccines, driving the market ... to a new study by University of Illinois researchers. ... driven by numerous factors," says Sheldon H. Jacobson, a ... science and of mathematics at the U. of I. ...
(Date:4/17/2014)... the University of California, San Diego School of Medicine ... have suffered a recent major loss are more likely ... , The study is published in this month,s issue ... , Because compassionate behaviors are associated with better health ... insights into ways to improve the outcomes of individuals ...
(Date:4/17/2014)... MD, was recently invited to submit a review ... Microbiology , one of the world,s foremost scientific ... specialist, and chair of the Department of Pediatrics ... analyzed the epidemiology and microbiology of co-infections during ... as more recent 2009 novel H1N1 pandemic. ...
(Date:4/17/2014)... MAYWOOD, Il. (April 17, 2014) Doctors who ... disease called lymphangioleiomyomatosis (LAM) can face an agonizing ... progression of the disease and help relieve shortness ... lung transplants, and sirolimus can cause potentially fatal ... said pulmonologist Dr. Daniel Dilling, medical director of ...
(Date:4/17/2014)... about one in five infants in the United States ... first several months after birth. Research into probiotic use ... the April 1, 2014 issue of the British ... study, "Probiotics and Infant Colic," concluding that the use ... colic did not reduce crying or fussing in ...
Breaking Medicine News(10 mins):Health News:Study recalculates costs of combination vaccines 2Health News:The ilk of human kindness 2Health News:Patients with rare lung disease face agonizing treatment dilemma 2Health News:Patients with rare lung disease face agonizing treatment dilemma 3Health News:New study says probiotic use for infant colic is not effective in reducing symptoms 2
... the reason why isolated women are less vulnerable to falling ill ... ,The study is an eye-opener to the upcoming proof that ... a clue to the reason why socially isolated men are prone ... have shown a connection between stress and immune function. But this ...
... Bachoud-Lévi, M.D., and colleagues of the French national institute ... Huntington's disease// who previously received intracerebral fetal neural grafts ... ,But the same investigators reported today that ... years and then began to decline over the next ...
... at University of California have gained valuable insights about ... , a finding that may eventually accelerate current research ... is a joint effort by Dr. Frank Sauer (UCR ... Munich) and other researchers from University of California. The ...
... School of Public Health are one of the 14 ... Environmental Health Sciences// (NIEHS) to study the association between ... is a new study to control the rising obesity ... an individual’s body size. Working with various city departments, ...
... Research Institutes, Inc (NDRI) in New York City ... the role// of social supports, spirituality, religiousness, life ... recovery from addiction. The study reveals markedly improved ... a decrease in stress when people were inclined ...
... fear regarding the elevated risk of lymphoma associated with ... has found that such treatments may not confer an ... be seen in the latest issue of Arthritis & ... been found to increase with worsening of the chronic ...
Cached Medicine News:Health News:Women Portray Stronger Immune Response As Compared to Men, Study Suggests 2Health News:Fetal Neural Grafts Improves Motor and Cognitive Function in Huntington Patients 2Health News:Drug Addiction Recovery Buffered by Spirituality 2Health News:No Lymphoma Risk From Rheumatoid Arthritis Drugs 2
Flattened points in vertical plane, straight shafts, cross action, round handle....
... cross action. Round handle. Divides nucleus for ... Nuclei of any hardness can be pre-chopped ... of pre-chopped nuclear fragments is rapid. Risk ... diminished. Shortened ultra sound time and minimal ...
1.5 mm inner cutting edge....
Nucleus chopper....
Medicine Products: